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Advancesinbonemarrowpathologycontinuedapacein2008.
Somefieldssawincreasingconsensus,othersvigorousdebate!
The following are a personal selection of the highlights.
Myeloproliferative neoplasms
The fiftieth anniversary of Blood saw the publication of a
series of excellent review articles. The myeloproliferative
disorders [1] were first characterised by Gustav Heuck who
described myelofibrosis (MF) in 1879. Louis Henri Vaquez
described polycythemia vera (PV) in 1892. Essential
thrombocythemia (ET) followed somewhat later in 1934
when Emil Epstein and Alfred Goedel recognised it as a
distinct clinical syndrome. William Dameshek, however,
noted the overlapping clinical features of the three disorders
and preferred to consider them ‘closely interrelated’. This
clinical observation has considerable relevance to later
developments, in particular the identification of JAK2
V617F
in all three myeloproliferative neoplasms (MPNs). Currently,
JAK2
V617F gene dosage is thought to distinguish PV from
JAK2
V617F-positive ET. Familial studies have given support
to the idea that additional inherited alleles are implicated in
the pathogenesis of MPNs and that these remain unidenti-
fied. It is also possible that there are inherited modifiers that,
whilst not predisposing to the development of MPN, may
contribute to the clinical phenotype of JAK2
V617F-positive
MPN. In addition, data suggest that there may be ‘pre-JAK2’
alleles responsible for clonal haemopoiesis that does not
manifest as a clinical MPN. The progression of JAK2
V617F-
positive MPN to JAK2
V617F-negative acute leukaemia
supports the existence of a JAK2
V617F-negative progenitor.
Studies of JAK2
V617F-negative MPNs have identified variant
MPLW515L in JAK2
V617F-negative ET associated with
marked thrombocytosis and myelofibrosis.
A second excellent review on the history of myelopro-
liferative disorders before and after Dameshek gives further
insight into the history of the haematology of the MPNs [2].
The revised 2008 World Health Organisation (WHO)
classification included significant revisions to the classifi-
cation of MPN, including their designation as ‘neoplasms’
and the introduction of ‘primary myelofibrosis’ as a
replacement term for ‘chronic idiopathic myelofibrosis’
[3]. Clinical guidance and a useful series of diagnostic
algorithms were published by Tefferi and Vardiman [4].
The importance of both the bone marrow biopsy and
molecular characterisation is emphasised. The authors
remind us that not all cases can be classified and these
should be placed into the ‘MPN, unclassifiable’ category
when this is the case and closely followed to monitor any
changes that might warrant revision of the diagnosis.
Spivak and Silver [5] emphasised the variability of the
phenotype of the MPNs and the changes that may take place
over time as the disease progresses. The ongoing controversy
over the reliability of histology of the bone marrow in
distinguishing the categories of MPN and the ability to
recognise a ‘pre-fibrotic’ phase of primary myelofibrosis is
discussed and an alternative proposal based on clinical
parameters is proposed. The biologically unsatisfactory
adoption of ‘primary’ myelofibrosis was noted. It is clear that
J Hematopathol (2009) 2:42–44
DOI 10.1007/s12308-009-0025-0
J. van der Walt (*)
Department of Histopathology, St Thomas’ Hospital,
Westminster Bridge Road,
London SE1 7EH, UK
e-mail: jon.vanderwalt@kcl.ac.ukalthough substantial progress in molecular classification of
PV, ETand MF has been made, there is much still to be done
beforeunanimityexistsinthe classificationofthese disorders.
It seems Dameshek was right. They are indeed ‘closely
interrelated’. Cytogenetic studies of BCR-ABL1-negative
MPNs lend further support to this view. In a comprehensive
review, Reilly [6] recorded that the incidence of
cytogenetic abnormalities in MPNs varied from 30% in
MF to less than 5% in ET and that no specific
abnormalities were found. These abnormalities may,
however, be secondary subclones resulting from genetic
instability of the original clone. Certain abnormalities
such as trisomy 8 and 12q- may, however, indicate that
an inferior prognosis and the cytogenetic profiling of
MPNs is therefore of value [6].
The presence of JAK2
V617F may be of use in the
distinction of fibrotic myelodysplastic syndrome (MDS)
from primary myelofibrosis. Olsen et al. [7] analysed
archived fixed material using real-time polymerase chain
reaction (PCR) for JAK2
V617F and found that they could
separate fibrotic MPN from myelodysplasia with fibrosis.
PCR for JAK2
V617Fin paraffin-embedded tissues may prove
to be very useful in cases with morphology intermediate
between MPN and fibrotic disorders.
Myelodysplastic syndromes
The International Working Group on Morphology of
Myelodysplastic Syndrome published consensus proposals
for the definition and enumeration of myeloblasts and ring
sideroblasts [8]. The group reviewed the morphological
features of bone marrows from all subtypes of myelodys-
plastic syndrome and agreed on a set of recommendations:
(1) agranular or granular blast cells be defined (replacing
the previous types I, II and III blasts), (2) dysplastic
promyelocytes be distinguished from cytologically normal
promyelocytes and from granular blast cells, (3) sufficient
cells be counted to give a precise blast percentage,
particularly at thresholds that are important for diagnosis
or prognosis and (4) ring sideroblasts be defined as erythro-
blasts in which there are a minimum of five siderotic granules
covering at least a third of the nuclear circumference.
Clearer definitions are likely to improve precision in the
diagnosis and classification of myelodysplastic syndrome
in the context of the WHO classification. However, no
immunocytochemical data were provided and the designa-
tion of ‘blast’ in the context of the bone marrow biopsy was
not discussed. Caution is therefore needed in comparing
counts of CD34
+ progenitors in the bone marrow biopsy
with the aspirate blast count.
The 5q- syndrome was first described in 1974 by
Van den Berghe et al., and the condition has been
recently reviewed [9]. In comparison with other types of
MDS, 5q- syndrome is characterised by isolated del(5q)
and characteristic megakaryocytes with hypolobated nu-
clei. Of great interest is that lenalidomide therapy induces
haematological remission which has been documented to
occur in the absence of cytogenetic remission, suggesting
that the action of lenalidomide is not specifically on the
5q- clone. It is suggested that loss of an RPS14 allele
accounts for the characteristic phenotype, but further
investigation is required.
The myelodysplastic/myeloproliferative neoplasms
Historical difficulties in classifying disease with dysplastic
marrows that also showed proliferation lead to the WHO
classification introducing the MDS/MPN category to
provide a less restrictive definition [10]. This ‘spotlight
review’ [10] provides a concise overview of the MDS/MPN
category which includes atypical chronic myeloid leukae-
mia (aCML), chronic myelomonocytic leukaemia (CMML),
MDS/MPN, unclassifiable (MDS/MPNu), refractory anae-
mia with ring sideroblasts and thrombocytosis (RARS-T),
5q-/JAK2-positive atypical myeloproliferative disease and
atypical myeloproliferative disease associated with isolated
isochromosome 17q. It is emphasised that morphological
features are often not diagnostic and that a multiparameter
approach is required for the ‘clinicopathological assigna-
tion’ of these entities. By definition, the Philadelphia
chromosome or BCR/ABL1 fusion gene is absent, and in
fact, no specific genetic defects have been identified.
Likewise, cases with rearranged PDGFRA or PDGFRB
genes are now classified separately. Attention to both
peripheral blood and bone marrow is required, exempli-
fied by the distinction of aCML from typical CML by the
presence of peripheral dysgranulopoiesis and lack of
basophilia. Whilst the classical manifestation of CMML
is peripheral monocytosis, rare cases fall below the 1000×
10
9/L threshold and the presence of bone marrow
monocyte proliferation allows the diagnosis of ‘bone
marrow predominant’ CMML. Immunocytochemistry is
of importance in the diagnosis [10] and may show
architectural features such as ‘myelomonocytic’ nodules
not apparent in the aspirate [11].
Juvenile myelomonocytic leukaemia (JMML) presents
between birth and 6 years of age [12] and lacks any causal
chromosomal abnormalities. However, the pathogenesis is
known to involve dysregulation and aberrant signal
transduction of the Ras pathway, providing a model for
the investigation of these abnormalities and through its
association with neurofibromatosis type 1 and Noonan
syndrome, a teaching tool for the exploration of inherited
predispositions to cancer [12].
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and abnormalities of PDGFRA, PDGFRB and FGFR1
Five years have passed since the identification of
FIP1L1-PDGFRA fusion gene [13], and the importance
of this finding has been recognised in the revised WHO
classification [3]. In a comprehensive review, Gotlib and
Cools describe the molecular separation of these clonal
eosinophilias from reactive eosinophilia associated with
infection, hypersensitivity, lymphomas, other myeloid
neoplasms and T cell populations with aberrant phenotype
and abnormal cytokine production. Several variant
PDGFRA, PDGFRB and FGFR1 fusion genes have been
identified often in unique case reports. PDGFRB rear-
rangements are rare in other defined entities such as
JMML, aCML, etc., but recognition is essential in view of
the sensitivity of such cases to imatinib [13]. Systemic
mastocytosis with eosinophilia has also been shown to be
FIP1L1-PDGFRA-positive. The dramatic response to
imatinib is highlighted.
Lymphoid lesions in the bone marrow
Sézary syndrome (SS) is often considered to represent a
leukaemic form of mycosis fungoides (MF). However,
the 2008 edition of the WHO classification lists SS and
MF as separate lymphomas. Van Doorn et al. [14]
provide support for this view. Using array-based compar-
ative genomic hybridisation and microarray analysis of
gene expression, chromosomal alterations in MF were
characterised by gains on chromosomes 1 and 7 and loss on
9, whereas SS demonstrated gains on chromosomes 8 and
17 and loss on 10. These changes suggest that the pathogen-
esis of MF and SS follow different pathways and are
distinct.
Splenic marginal zone lymphoma with circulating
villous lymphocytes (SMZL) generally has an indolent
clinical course, but is known to progress. Dungarwalla et al.
[15] studied 48 cases of SMZL and found progression in
31. The cases that progressed to large B cell lymphoma had
significantly greater peripheral lymph node involvement
and a higher incidence of serum IgM paraprotein. The rate
of transformation to large B cell lymphoma was 19% (9/
48). In four cases, the transformation was in the bone
marrow. The prognosis was worse in these cases compared
with those with lymph node transformation, being refractory
to treatment. This paper emphasises the importance of a bone
marrow biopsy in patients with SMZL showing evidence of
clinical progression.
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